{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T21:08:14Z","timestamp":1774386494137,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T00:00:00Z","timestamp":1405900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T00:00:00Z","timestamp":1405900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/bmt.2014.146","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T14:59:23Z","timestamp":1405954763000},"page":"1146-1154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis"],"prefix":"10.1038","volume":"49","author":[{"given":"H","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L-P","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D-H","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K-Y","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-S","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-H","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X-H","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-Z","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F-R","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-Z","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-Y","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X-J","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,21]]},"reference":[{"key":"BFbmt2014146_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL . Chronic myeloid leukemia. New Engl J Med 1999; 340: 1330\u20131340.","journal-title":"New Engl J Med"},{"key":"BFbmt2014146_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","volume":"131","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, Kantarjian HM . Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131: 207\u2013219.","journal-title":"Ann Intern Med"},{"key":"BFbmt2014146_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0002-9343(93)90122-6","volume":"94","author":"PM Derderian","year":"1993","unstructured":"Derderian PM, Kantarjian HM, Talpaz M, O'Brien S, Cork A, Estey E et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993; 94: 69\u201374.","journal-title":"Am J Med"},{"key":"BFbmt2014146_CR4","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","volume":"86","author":"S Sacchi","year":"1999","unstructured":"Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86: 2632\u20132641.","journal-title":"Cancer"},{"key":"BFbmt2014146_CR5","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3324\/haematol.13068","volume":"93","author":"F Palandri","year":"2008","unstructured":"Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica 2008; 93: 1792\u20131796.","journal-title":"Haematologica"},{"key":"BFbmt2014146_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3109\/10428194.2011.627480","volume":"53","author":"FE Nicolini","year":"2012","unstructured":"Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL et al. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leuk Lymphoma 2012; 53: 907\u2013914.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2014146_CR7","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1002\/cncr.25123","volume":"116","author":"G Saglio","year":"2010","unstructured":"Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 2010; 116: 3852\u20133861.","journal-title":"Cancer"},{"key":"BFbmt2014146_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/leu.2011.355","volume":"26","author":"FJ Giles","year":"2012","unstructured":"Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 2012; 26: 959\u2013962.","journal-title":"Leukemia"},{"key":"BFbmt2014146_CR9","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513\u2013521.","journal-title":"Haematologica"},{"key":"BFbmt2014146_CR10","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.leukres.2011.01.001","volume":"35","author":"Y Luo","year":"2011","unstructured":"Luo Y, Zhao Y, Tan Y, Shi J, Han X, Zheng Y et al. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia. Leuk Res 2011; 35: 1307\u20131311.","journal-title":"Leuk Res"},{"key":"BFbmt2014146_CR11","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"S Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880\u20131885.","journal-title":"Blood"},{"key":"BFbmt2014146_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/sj.bmt.1705683","volume":"40","author":"H Menzel","year":"2007","unstructured":"Menzel H, von Bubnoff N, Hochhaus A, Haferlach C, Peschel C, Duyster J . Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib. Bone Marrow Transplant 2007; 40: 83\u201384.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014146_CR13","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041\u20136051.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014146_CR14","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFbmt2014146_CR15","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292\u20132302.","journal-title":"Blood"},{"key":"BFbmt2014146_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","volume":"38","author":"XJ Huang","year":"2006","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291\u2013297.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014146_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbmt.2008.11.025","volume":"15","author":"XJ Huang","year":"2009","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Treatment of acute leukemia with unmanipulated HLA-mismatched\/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257\u2013265.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014146_CR18","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1158\/1078-0432.CCR-09-0691","volume":"15","author":"H Xiao-Jun","year":"2009","unstructured":"Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009; 15: 4777\u20134783.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2014146_CR19","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","volume":"107","author":"DP Lu","year":"2006","unstructured":"Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065\u20133073.","journal-title":"Blood"},{"key":"BFbmt2014146_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/07853890801908903","volume":"40","author":"H Xiao-Jun","year":"2008","unstructured":"Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Huan C, Wei H et al. HLA-mismatched\/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008; 40: 444\u2013455.","journal-title":"Ann Med"},{"key":"BFbmt2014146_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bbmt.2010.07.023","volume":"17","author":"XJ Huang","year":"2011","unstructured":"Huang XJ, Xu LP, Liu KY, Liu DH, Chen H, Liu YR et al. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2011; 17: 649\u2013656.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014146_CR22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3324\/haematol.10570","volume":"92","author":"XJ Huang","year":"2007","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W . Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched\/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414\u2013417.","journal-title":"Haematologica"},{"key":"BFbmt2014146_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s10875-008-9193-4","volume":"28","author":"XJ Huang","year":"2008","unstructured":"Huang XJ, Wang Y, Liu DH, Xu LP, Chen H, Chen YH et al. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia\u2014feasibility and safety study. J Clin Immunol 2008; 28: 390\u2013397.","journal-title":"J Clin Immunol"},{"key":"BFbmt2014146_CR24","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program. Leukemia 2003; 17: 2474\u20132486.","journal-title":"Leukemia"},{"key":"BFbmt2014146_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1751-553X.2007.00962.x","volume":"30","author":"YZ Qin","year":"2008","unstructured":"Qin YZ, Liu YR, Zhu HH, Li JL, Ruan GR, Zhang Y et al. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 2008; 30: 317\u2013323.","journal-title":"Int J Lab Hematol"},{"key":"BFbmt2014146_CR26","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.leukres.2013.06.003","volume":"37","author":"YZ Qin","year":"2013","unstructured":"Qin YZ, Jiang Q, Jiang H, Li JL, Li LD, Zhu HH et al. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level? Leuk Res 2013; 37: 1035\u20131040.","journal-title":"Leuk Res"},{"key":"BFbmt2014146_CR27","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","volume":"117","author":"Q Jiang","year":"2011","unstructured":"Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011; 117: 3032\u20133040.","journal-title":"Blood"},{"key":"BFbmt2014146_CR28","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, Muller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172\u20132175.","journal-title":"Leukemia"},{"key":"BFbmt2014146_CR29","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530\u20133539.","journal-title":"Blood"},{"key":"BFbmt2014146_CR30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R . How I treat CML blast crisis. Blood 2012; 120: 737\u2013747.","journal-title":"Blood"},{"key":"BFbmt2014146_CR31","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1200\/JCO.2011.36.0693","volume":"29","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian HM, O'Brien S, Shan J, Quintas-Cardama A, Garcia-Manero G et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol 2011; 29: 4260\u20134265.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2014146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014146","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T17:15:07Z","timestamp":1648055707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2014146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,21]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFbmt2014146"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2014.146","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,21]]},"assertion":[{"value":"14 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}